Who are Latanoprost plus adjunctive glaucoma medication's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/latanoprost-plus-adjunctive-glaucoma-medication.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Latanoprost plus adjunctive glaucoma medication — Competitive Intelligence Brief

Latanoprost plus adjunctive glaucoma medication (Latanoprost plus adjunctive glaucoma medication) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Prostaglandin analog with adjunctive glaucoma agent. Area: Ophthalmology.

marketed Prostaglandin analog with adjunctive glaucoma agent FP prostaglandin receptor (latanoprost component); adjunctive target unknown Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Latanoprost plus adjunctive glaucoma medication (Latanoprost plus adjunctive glaucoma medication) — Sight Sciences, Inc.. Latanoprost is a prostaglandin F analog that increases uveoscleral outflow of aqueous humor to lower intraocular pressure in glaucoma, combined with an adjunctive agent to enhance this effect.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Latanoprost plus adjunctive glaucoma medication TARGET	Latanoprost plus adjunctive glaucoma medication	Sight Sciences, Inc.	marketed	Prostaglandin analog with adjunctive glaucoma agent	FP prostaglandin receptor (latanoprost component); adjunctive target unknown

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Prostaglandin analog with adjunctive glaucoma agent class)

Sight Sciences, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Latanoprost plus adjunctive glaucoma medication — Competitive Intelligence Brief. https://druglandscape.com/ci/latanoprost-plus-adjunctive-glaucoma-medication. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab